

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**国药集团**  
SINOPHARM

**CHINA TRADITIONAL CHINESE MEDICINE HOLDINGS CO. LIMITED**  
**中國中藥控股有限公司**

*(Incorporated in Hong Kong with limited liability)*  
**(Stock Code: 570)**

**CHANGE OF EXECUTIVE DIRECTOR, CHAIRMAN AND AUTHORISED REPRESENTATIVE**

**RETIREMENT OF EXECUTIVE DIRECTOR AND CHAIRMAN**

The board (the “**Board**”) of directors (the “**Directors**”) of China Traditional Chinese Medicine Holdings Co. Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Mr. WU Xian (“**Mr. WU**”) has reached retirement age and submitted to retire as the executive Director and chairman of the Board (the “**Chairman**”) on 29 April 2022, with effect from 12 May 2022. Mr. WU has vacated from the office as chairman of each of the nomination committee (the “**Nomination Committee**”) and the strategic committee (the “**Strategic Committee**”) of the Board upon his retirement as an executive Director.

Mr. WU has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to express its sincere gratitude to Mr. WU for his valuable contribution to the Group during his tenure of service.

**APPOINTMENT OF EXECUTIVE DIRECTOR AND CHAIRMAN**

The Board is pleased to announce that Mr. CHEN Yinglong (“**Mr. CHEN**”) has been appointed as an executive Director and the Chairman, with effect from 12 May 2022. Mr. CHEN has also been appointed as the chairman of each of the Nomination Committee and the Strategic Committee.

The biographical details of Mr. CHEN are set out below:

Mr. CHEN Yinglong, aged 51, was appointed to the Board on 12 May 2022. Mr. CHEN graduated from Heilongjiang University with a bachelor degree of English majoring in English Literature in 1993 and completed the master course of Management Science and Engineering in School of Management of Harbin Institute of Technology in 1999. Mr. CHEN has the professional qualification of senior enterprise information manager and senior economist. Mr. CHEN was the business manager of the first business department of Harbin Metals and Minerals Import and Export Corporation from December 1993 to September 1994; the first representative of Harbin branch of Eisenberg Group United Development Co., Ltd. from September 1994 to October 1999; the general manager of Harbin Runhe Technology Development Co., Ltd. from October 1999 to April 2004; a director and general manager of Harbin Baida Pharmaceutical Co., Ltd. from April 2004 to November 2009; a manager of the raw material department and successively a manager of the safety and environmental protection department of China National Pharmaceutical Industry Company Limited from November 2009 to August 2010; the deputy general manager, general legal adviser and secretary of the board of directors of China Traditional Chinese Medicine Co. Ltd. (formerly known as China National Corp. of Traditional & Herbal Medicine) from August 2010 to December 2018. He served as a vice president of the Company from December 2018 to May 2020, during which he was also the standing committee member of the municipal committee and deputy mayor of Baishan City of Jilin Province. He has been director of public affairs department of China National Pharmaceutical Group Corporation since May 2020. Mr. CHEN is currently the deputy Party secretary of the Company and the chairman of the board of directors, general manager and provisional deputy Party secretary of the China Traditional Chinese Medicine Co. Ltd.

Save as disclosed above, Mr. CHEN (i) does not hold any other position within the Group; (ii) has not held directorships in any other listed companies in the past three years; (iii) has not held any other major appointment and professional qualifications; and (iv) does not have any relationship with any directors, senior management or substantial or controlling shareholders of the Company (as defined under the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”)).

Mr. CHEN will enter into an employment agreement with the Company in relation to his appointment as the executive Director and the Chairman with effect from 12 May 2022, which shall automatically be effective hereafter. He shall hold office only until the next general meeting of the Company and shall then be eligible for re-election. Thereafter, Mr. CHEN is subject to retirement by rotation and re-election in accordance with the articles of association of the Company. The aggregate remuneration of Mr. CHEN as the executive Director and Chairman is RMB2,450,000 per annum, which is determined by the remuneration and evaluation committee of the Board in accordance with reference to his duties, market rate and his time, effort, expertise and responsibilities to be exercised on the Group’s affairs and with the Company’s remuneration policy.

As at the date of this announcement, Mr. CHEN does not have any interest in the shares, underlying shares or debentures of the Company and/or its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, there are no other matters concerning Mr. CHEN that need to be brought to the attention of the shareholders of the Company, nor is there any information relating to Mr. CHEN that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to welcome to Mr. CHEN on his appointment as the executive Director and the Chairman.

## **CHANGE OF AUTHORISED REPRESENTATIVE**

The Board further announces that Mr. WU has ceased to act as an authorised representative (the “**Authorised Representative**”) of the Company under Rule 3.05 of the Listing Rules following his retirement, and Mr. CHEN has been appointed as the Authorised Representative with effect from 12 May 2022.

By Order of the Board  
**China Traditional Chinese Medicine Holdings Co. Limited**  
**CHENG Xueren**  
*Executive Director and Managing Director*

Hong Kong, 12 May 2022

*As at the date of this announcement, the Board comprises twelve Directors, of which Mr. CHEN Yinglong, Mr. CHENG Xueren, and Mr. YANG Wenming are executive Directors; Mr. YANG Shanhua, Ms. LI Ru, Mr. YANG Binghua, Mr. WANG Kan and Mr. KUI Kaipin are non-executive Directors; and Mr. XIE Rong, Mr. YU Tze Shan Hailson, Mr. QIN Ling and Mr. LI Weidong are independent non-executive Directors.*